Boston Tech
Prime Medicine Beat Beam in Gene-Editing Arbitration, and Cambridge Called It Family Therapy
Prime Medicine's July 8 Beam ruling cleared its AATD gene-editing program, giving Cambridge biotech one more extremely local way to compete.
Boston Tech
Prime Medicine's July 8 Beam ruling cleared its AATD gene-editing program, giving Cambridge biotech one more extremely local way to compete.
Boston Tech
Vertex's July 1 FDA expansion makes Casgevy available to children ages 2 and up, a major Boston biotech milestone with real access hurdles.